Dr. Nasser Hanna outlines the possible benefits of consolidation chest radiation for small cell lung cancer patients who respond well to chemotherapy.
The doctors discuss the circumstances under which small cell lung cancer patients should receive prophylactic cranial irradiation.
Dr. Nasser Hanna discusses the SQUIRE trial of the EGFR antibody Necitumumab in patients with squamous lung cancer. Though it achieved a statistical increase in OS, he does not consider it clinically relevant.
The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.
The doctors discuss the new FDA-approved drug for ALK positive lung cancer patients, Zykadia (ceritinib), including the dosage level, potential side effects and the ability of Zykadia to impact brain metastases.
"Dead negative," is how Dr. Nasser Hanna describes results of a phase 3 study that examined how patients with high MET expression did on the drug MetMab (onartuzumab).
Lung cancer patients with high MET amplification appear to do well on Xalcori (crizotinib), a drug that is approved for ALK positive patients.
Lung cancer patients with the EGFR mutation who had progressed on other drugs did well on a new drug in clinical trial, though one particular side effect concerns some.
Fibroblast growth factor receptor (FGFR) mutations may play a role in the growth of squamous cell lung cancer. Dr. Jonathan Riess talks about what they are learning in this area.
EGFR positive lung cancer patients who had seen cancer progression responded well to a new drug in an early clinical trial.
"HSP 90 inhibitors are a really cool class of drugs..." states Dr. Melissa Johnson of the Robert H. Lurie Comprehensive Cancer Center as she describes what researchers are learning about these drugs still in early development. February 2014.
Dr. Leena Gandhi of Dana-Farber Cancer Institute sees great potential in immune therapies for lung cancer. In this video, she expresses her hope and excitement for what the future may hold. February 2014.
An analysis of two large studies of EGFR lung cancer patients tried to determine if Gilotrif helped patients live longer.
Progression-free survival is something that doctors measure to determine how well a patient responds to a particular treatment. But does it translate to increased overall survival?
A genetic mutation and a leukemia drug may provide new hope for patients with squamous cell lung cancer patients.
Drs. Nasser Hanna, Melissa Johnson and Jack West discuss results of a phase 2 trial presented at ASCO 2014 that studied if adding Avastin (bevicizumab) to Tarceva helped EGFR positive lung cancer patients increase progression-free survival. June 2014.
Dr. Joel Neal of Stanford University Medical Center talks about FGFR - fibroblast growth factor receptor - and how it can impact non-small cell lung cancer growth.
Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute describes what research indicates may be more successful treatments for EGFR lung cancer patients.
Dr. Jonathan Goldman discusses a drug currently being studied that may make lung cancer tumors more susceptible to treatment. February 2014.
How much detail is needed when determining how to treat lung cancer? Should patients be tested for all the mutations that may exist within their tumors? Dr. Jonathan Riess discusses this issue and how he makes decisions regarding his own patients.